- ISIN
- US71722W1071
- CUSIP
- 71722W107
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 25, 2019
Highlights
- Market Cap
- $877.12M
- Enterprise Value
- $699.51M
- EPS (TTM)
- -$1.69
- Total Revenue (TTM)
- $204.89M
- Gross Profit (TTM)
- $174.02M
- EBITDA (TTM)
- $11.49M
- Year Range
- $7.61 - $18.31
- Target Price
- $24.40
- ROA (TTM)
- -41.60%
- ROE (TTM)
- 37.67%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PHAT Performance Chart
Phathom Pharmaceuticals, Inc. (PHAT) is down 35.6% since the beginning of the year. At $11 per share, PHAT is trading 41.6% below its 52-week high of $18. Investors who bought $1,000 worth of PHAT shares 5 years ago would now be looking at an investment worth $307.
Loading charts...
Returns By Period
Phathom Pharmaceuticals, Inc. (PHAT) has returned -35.56% so far this year and 2.59% over the past 12 months.
Phathom Pharmaceuticals, Inc.
- 1D
- -1.75%
- 1M
- -5.65%
- YTD
- -35.56%
- 6M
- -40.18%
- 1Y
- 2.59%
- 3Y*
- -6.67%
- 5Y*
- -21.02%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
PHAT Monthly Returns History
Based on dividend-adjusted daily data since Oct 25, 2019, PHAT's average daily return is +0.11%, while the average monthly return is +1.66%. At this rate, an investment would double in approximately 3.5 years.
Historically, 51% of months were positive and 49% were negative. The best month was Jun 2025 with a return of +125.7%, while the worst month was Nov 2024 at -48.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.
On a daily basis, PHAT closed higher 49% of trading days. The best single day was Jun 6, 2025 with a return of +90.2%, while the worst single day was Jan 4, 2023 at -31.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -17.60% | -8.12% | -11.54% | 0.81% | -14.38% | 11.47% | -35.56% | ||||||
| 2025 | -26.23% | -7.85% | 13.59% | -31.58% | -0.93% | 125.65% | -10.95% | 42.62% | -3.37% | 15.12% | 15.28% | 6.21% | 104.31% |
| 2024 | -26.62% | 59.70% | -0.75% | -14.97% | 4.32% | 9.34% | 14.76% | 39.76% | 9.44% | -5.14% | -48.28% | -8.46% | -11.06% |
| 2023 | 6.33% | -28.25% | -16.59% | 49.86% | 9.91% | 21.77% | 6.22% | -5.39% | -27.94% | -10.32% | -24.84% | 30.62% | -18.63% |
| 2022 | -14.59% | 7.92% | -24.93% | -4.92% | -44.59% | 17.71% | 9.12% | -7.27% | 29.74% | -4.33% | -5.85% | 12.42% | -42.96% |
| 2021 | 15.89% | 14.42% | -14.73% | 2.56% | -8.23% | -4.24% | -5.17% | 10.87% | -9.81% | -26.70% | -23.76% | 9.64% | -40.79% |
Benchmark Metrics
Phathom Pharmaceuticals, Inc. has an annualized alpha of 8.05%, beta of 1.34, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since October 25, 2019.
- This stock participated in 120.53% of S&P 500 Index downside but only 31.34% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 8.05%
- Beta
- 1.34
- R²
- 0.09
- Upside Capture
- 31.34%
- Downside Capture
- 120.53%
Return for Risk
Risk / Return Rank
PHAT ranks 43 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Phathom Pharmaceuticals, Inc. (PHAT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PHAT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.99 | ||
| Sortino ratioReturn per unit of downside risk | -2.25 | ||
| Omega ratioGain probability vs. loss probability | 1.06 | 1.37 | -0.31 |
| Calmar ratioReturn relative to maximum drawdown | 0.05 | 2.78 | -2.73 |
| Martin ratioReturn relative to average drawdown | 0.11 | 12.44 | -12.33 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Phathom Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Phathom Pharmaceuticals, Inc. was 95.81%, occurring on May 8, 2025. The portfolio has not yet recovered.
The current Phathom Pharmaceuticals, Inc. drawdown is 80.42%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -95.81%May 2025 | 4y 11mo | — | 6y 15dJun 2020 - now |
COVID crash2020 | -42.45%Mar 2020 | 1mo 5d | 1mo 11d | 2mo 16dFeb 2020 - May 2020 |
2019 bear market2019 | -30.89%Dec 2019 | 1mo 7d | 5d | 1mo 12dNov 2019 - Dec 2019 |
2020 bear market2020 | -20.63%Jan 2020 | 6d | 25d | 1mo 1dDec 2019 - Jan 2020 |
2020 correction2020 | -19.54%May 2020 | 11d | 8d | 19dMay 2020 - May 2020 |
Drawdown Indicators
| PHAT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.81% | -56.78% | -39.03% |
Max Drawdown (1Y)Largest decline over 1 year | -48.89% | -9.10% | -39.79% |
Max Drawdown (3Y)Largest decline over 3 years | -88.26% | -18.90% | -69.36% |
Max Drawdown (5Y)Largest decline over 5 years | -93.78% | -25.43% | -68.35% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -80.42% | -1.80% | -78.62% |
Average DrawdownAverage peak-to-trough decline | -63.46% | -10.71% | -52.75% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.35% | 2.03% | +22.32% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Phathom Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Phathom Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PHAT relative to other companies in the Biotechnology industry. Currently, PHAT has a P/S ratio of 3.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PHAT
Add Phathom Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PHAT